CAN VERY LOW DOSE RIVAROXABAN (VLDR) IN ADDITION TO DUAL ANTIPLATELET THERAPY (DAPT) IMPROVE THROMBOTIC STATUS IN ACUTE CORONARY SYNDROME (ACS)

Medicine & Life Sciences

1. Thrombosis 100%
2. Acute Coronary Syndrome 35%
3. Hemorrhage 22%
4. Non-ST Elevated Myocardial Infarction 15%
5. Rivaroxaban 15%
6. Fibrinolytic Agents 14%
7. Coronary Occlusion 13%
8. Platelet Aggregation Inhibitors 13%
9. Unstable Angina 13%
10. Plasminogen Activator Inhibitor 1 13%
11. Fibrinogen 11%
12. Anticoagulants 10%
13. Rupture 10%
14. Infarction 9%
15. Coronary Vessels 9%
16. Therapeutics 9%